- Home
- SGD vs DRMA Comparison
SGD vs DRMA Comparison
Compare SGD & DRMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGD
- DRMA
- Stock Information
- Founded
- SGD 2021
- DRMA 2014
- Country
- SGD United States
- DRMA United States
- Employees
- SGD N/A
- DRMA N/A
- Industry
- SGD
- DRMA Biotechnology: Pharmaceutical Preparations
- Sector
- SGD
- DRMA Health Care
- Exchange
- SGD Nasdaq
- DRMA Nasdaq
- Market Cap
- SGD 1.8M
- DRMA 4.5M
- IPO Year
- SGD N/A
- DRMA 2021
- Fundamental
- Price
- SGD $0.83
- DRMA $0.71
- Analyst Decision
- SGD
- DRMA Strong Buy
- Analyst Count
- SGD 0
- DRMA 1
- Target Price
- SGD N/A
- DRMA $3.00
- AVG Volume (30 Days)
- SGD 59.0K
- DRMA 118.5K
- Earning Date
- SGD 08-22-2025
- DRMA 08-06-2025
- Dividend Yield
- SGD N/A
- DRMA N/A
- EPS Growth
- SGD N/A
- DRMA N/A
- EPS
- SGD N/A
- DRMA N/A
- Revenue
- SGD $175,906.00
- DRMA N/A
- Revenue This Year
- SGD N/A
- DRMA N/A
- Revenue Next Year
- SGD N/A
- DRMA N/A
- P/E Ratio
- SGD N/A
- DRMA N/A
- Revenue Growth
- SGD 253.11
- DRMA N/A
- 52 Week Low
- SGD $0.65
- DRMA $0.57
- 52 Week High
- SGD $9.98
- DRMA $5.00
- Technical
- Relative Strength Index (RSI)
- SGD 44.78
- DRMA 53.74
- Support Level
- SGD $0.75
- DRMA $0.61
- Resistance Level
- SGD $0.84
- DRMA $0.74
- Average True Range (ATR)
- SGD 0.08
- DRMA 0.06
- MACD
- SGD -0.00
- DRMA 0.01
- Stochastic Oscillator
- SGD 32.91
- DRMA 67.43
About SGD Safe and Green Development Corporation
Safe & Green Development Corp is a real estate development company that focuses on the development of sites using purpose built, prefabricated modules built from both wood & steel, sourced from one of Safe and Green Holdings factories. The company's business model is flexible and it anticipates developing properties on its own and also through joint ventures in which it partners with third-party equity investors or other developers.
About DRMA Dermata Therapeutics Inc.
Dermata Therapeutics Inc is a late-stage medical dermatology company focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical skin diseases and aesthetic applications. Its two product candidates, XYNGARI (formerly known as DMT310) and DMT410, incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its Spongilla technology platform will enable to development and formulation of singular and combination products that can target topical delivery of chemical compounds into the dermis for maximum treatment effect for a variety of inflammatory skin diseases. Dermata announced positive Phase 3 data from its STAR-1 clinical trial in March 2025.